Davis Polk advised the joint book-running managers and the co-managers in connection with the $349.3 million public offering of common stock by Portola Pharmaceuticals, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “PTLA.” 

Based in South San Francisco, California, Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Tyler P. Pender and Leeann Overstreet. The tax team included partner Rachel D. Kleinberg and associate K. Daniel Berman. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. Members of the Davis Polk team are based in the Northern California and New York offices. 

Copy link to share post